Subclinical atherosclerosis burden predicts cardiovascular events in individuals with diabetes and chronic kidney disease.
Cardiovascular events
Chronic kidney disease
Diabetes
Multiterritorial arterial ultrasound
Subclinical atherosclerosis
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
19 07 2019
19 07 2019
Historique:
received:
30
04
2019
accepted:
12
07
2019
entrez:
21
7
2019
pubmed:
22
7
2019
medline:
31
3
2020
Statut:
epublish
Résumé
Individuals with diabetes have remarkably high rates of cardiovascular morbidity and mortality. However, the incremental cardiovascular risk in diabetes is heterogeneous and has often been related to renal involvement. The purpose of this study was to analyse the prognostic value of subclinical atherosclerosis in determining the incidence of first cardiovascular events (CVEs) in individuals with diabetes and chronic kidney disease (CKD) compared to CKD individuals without diabetes. We included data from individuals with CKD with and without diabetes, free from pre-existing cardiovascular disease, from the NEFRONA cohort. Participants underwent baseline carotid and femoral ultrasound and were followed up for 4 years. All CVEs during follow-up were registered. Bivariate analysis and Fine-Gray competing risk models were used to perform the statistical analysis. During the mean follow-up time of 48 months, a total of 203 CVE was registered. 107 CVE occurred among participants without diabetes (19.58 per 1000 person-years) and 96 CVE occurred among participants with diabetes (44.44 per 1000 person-years). Following the competing risk analysis, the variables predicting CVEs in CKD individuals without diabetes were the number of territories with plaque at baseline (HR 1.862, 95% CI [1.432;2.240]), age (HR 1.026, 95% CI [1.003;1.049]) and serum concentrations of 25-OH vitamin D (HR 0.963, 95% CI [0.933;0.094]). The only variable predicting CVEs among CKD participants with diabetes was the number of territories with plaque at baseline (HR 1.782, 95% CI [1.393, 2.278]). For both models, concordance (C) index yielded was over 0.7. The burden of subclinical atherosclerosis is the strongest predictor of future CVEs in diabetic individuals with CKD. Early detection of subclinical atherosclerotic burden by multiterritorial vascular ultrasound could improve CVE prediction in this population.
Sections du résumé
BACKGROUND
Individuals with diabetes have remarkably high rates of cardiovascular morbidity and mortality. However, the incremental cardiovascular risk in diabetes is heterogeneous and has often been related to renal involvement. The purpose of this study was to analyse the prognostic value of subclinical atherosclerosis in determining the incidence of first cardiovascular events (CVEs) in individuals with diabetes and chronic kidney disease (CKD) compared to CKD individuals without diabetes.
METHODS
We included data from individuals with CKD with and without diabetes, free from pre-existing cardiovascular disease, from the NEFRONA cohort. Participants underwent baseline carotid and femoral ultrasound and were followed up for 4 years. All CVEs during follow-up were registered. Bivariate analysis and Fine-Gray competing risk models were used to perform the statistical analysis.
RESULTS
During the mean follow-up time of 48 months, a total of 203 CVE was registered. 107 CVE occurred among participants without diabetes (19.58 per 1000 person-years) and 96 CVE occurred among participants with diabetes (44.44 per 1000 person-years). Following the competing risk analysis, the variables predicting CVEs in CKD individuals without diabetes were the number of territories with plaque at baseline (HR 1.862, 95% CI [1.432;2.240]), age (HR 1.026, 95% CI [1.003;1.049]) and serum concentrations of 25-OH vitamin D (HR 0.963, 95% CI [0.933;0.094]). The only variable predicting CVEs among CKD participants with diabetes was the number of territories with plaque at baseline (HR 1.782, 95% CI [1.393, 2.278]). For both models, concordance (C) index yielded was over 0.7.
CONCLUSIONS
The burden of subclinical atherosclerosis is the strongest predictor of future CVEs in diabetic individuals with CKD. Early detection of subclinical atherosclerotic burden by multiterritorial vascular ultrasound could improve CVE prediction in this population.
Identifiants
pubmed: 31324183
doi: 10.1186/s12933-019-0897-y
pii: 10.1186/s12933-019-0897-y
pmc: PMC6639953
doi:
Types de publication
Comparative Study
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
93Références
J Am Coll Cardiol. 1990 Jan;15(1):196-203
pubmed: 2136873
J Am Soc Echocardiogr. 2008 Feb;21(2):93-111; quiz 189-90
pubmed: 18261694
Lancet. 2006 Jul 1;368(9529):29-36
pubmed: 16815377
Atherosclerosis. 2019 Mar;282:202-209
pubmed: 30600075
Circulation. 2002 Jun 18;105(24):2872-7
pubmed: 12070116
Diabetes Care. 2013 Sep;36(9):2582-90
pubmed: 23564923
Atherosclerosis. 2001 Jun;156(2):379-87
pubmed: 11395035
J Am Coll Cardiol. 2010 Dec 14;56(25):e50-103
pubmed: 21144964
Stroke. 2007 Nov;38(11):2873-80
pubmed: 17901390
Lancet Diabetes Endocrinol. 2015 Mar;3(3):198-206
pubmed: 25660575
Cardiovasc Diabetol. 2018 May 4;17(1):66
pubmed: 29728117
Nephrol Dial Transplant. 2014 Jul;29(7):1415-22
pubmed: 24586070
JACC Cardiovasc Imaging. 2014 Nov;7(11):1108-15
pubmed: 25459592
Eur Heart J. 2006 Nov;27(21):2580-7
pubmed: 16952925
Cerebrovasc Dis. 2004;18(4):346-9
pubmed: 15523176
Eur Heart J. 2016 Aug 1;37(29):2315-2381
pubmed: 27222591
Atherosclerosis. 2009 Jun;204(2):549-55
pubmed: 19281981
Clin J Am Soc Nephrol. 2016 Feb 5;11(2):287-96
pubmed: 26668022
Circulation. 2015 Dec 22;132(25):2424-47
pubmed: 26644329
PLoS One. 2017 Oct 18;12(10):e0186665
pubmed: 29045466
BMJ. 2006 Jan 14;332(7533):73-8
pubmed: 16371403
JACC Cardiovasc Imaging. 2016 Feb;9(2):176-92
pubmed: 26846937
Diabetes Care. 2011 Oct;34(10):2285-90
pubmed: 21844289
J Am Coll Cardiol. 2010 Apr 13;55(15):1600-7
pubmed: 20378078
Diabetes Obes Metab. 2018 Aug;20(8):2000-2003
pubmed: 29577540
Lancet Diabetes Endocrinol. 2015 Jul;3(7):514-25
pubmed: 26028594
Blood Press. 2018 Oct;27(5):262-270
pubmed: 29648468
J Am Coll Cardiol. 2016 Mar 22;67(11):1263-74
pubmed: 26988945
BMJ Open. 2016 Nov 24;6(11):e012457
pubmed: 27884845
N Engl J Med. 1998 Jul 23;339(4):229-34
pubmed: 9673301
Am J Cardiol. 2013 Mar 1;111(5):754-9
pubmed: 23266072
BMC Nephrol. 2010 Jul 07;11:14
pubmed: 20609210
Diabet Med. 2009 Feb;26(2):142-8
pubmed: 19236616
J Clin Endocrinol Metab. 2012 May;97(5):1434-42
pubmed: 22419711
Atherosclerosis. 2012 Jan;220(1):128-33
pubmed: 21764060
Cardiovasc Diabetol. 2016 Mar 05;15:43
pubmed: 26944724
Circulation. 2004 Feb 24;109(7):855-60
pubmed: 14757692
Diabetes Care. 2004 Dec;27(12):2898-904
pubmed: 15562204
Diabetologia. 2018 May;61(5):1203-1211
pubmed: 29423580
J Atheroscler Thromb. 2018 Jan 1;25(1):55-64
pubmed: 28179606
Atherosclerosis. 2018 Sep;276:50-57
pubmed: 30032025
J Am Coll Cardiol. 2017 Jul 18;70(3):301-313
pubmed: 28705310
Diabetes Care. 2014;37(1):144-8
pubmed: 24062319
Circulation. 2015 Jun 16;131(24):2104-13
pubmed: 25882487
Cardiovasc Diabetol. 2018 Dec 7;17(1):156
pubmed: 30526614
Stroke. 2011 Apr;42(4):972-8
pubmed: 21311059
BMJ. 2002 Apr 20;324(7343):939-42
pubmed: 11964337
Diabetes Care. 2015 Mar;38(3):521-8
pubmed: 25524951
J Cardiovasc Comput Tomogr. 2015 Sep-Oct;9(5):406-14
pubmed: 26043963